PBMs made billions marking up speciality drugs by more than 1,000 percent: FTC

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through vertical integration, industry dominance and marking up the prices of speciality drugs. The report specifically looked at the business practices of the Caremark Rx, Express Scripts and OptumRx,...